Project Grant R15HL096097

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $117,000 Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) effective July 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This proof-of-concept study will evaluate the feasibility and preliminary efficacy of aerobic exercise as a countermeasure to the harmful cardiometabolic effects associated with night shift work. The research addresses...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded $614,843 to Massachusetts General Hospital's Research Management Division for a five-year investigation beginning May 1, 2026 and concluding February 28, 2031. The funded research examines the relationship between indexed exercise blood pressure (systolic blood pressure normalized to oxygen consumption, or SBP/VO2) and adverse vascular...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $721,237 Project Grant to the University of California, Los Angeles (UCLA) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the neural mechanisms by which inspiratory muscle training (IMT) reduces blood pressure in patients with obstructive sleep apnea (OSA). The four-year research initiative, effective September 1, 2025 through June 30, 2029, will examine whether IMT lowers...

This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), totals $248,919 and supports research conducted by The Johns Hopkins University in Baltimore, Maryland from June 1, 2026 through April 30, 2029. The research investigates skeletal muscle metabolism and exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF), the fastest-growing form of heart failure. The...

Project Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Trustees of Boston University a $1.27 million Project Grant (CFDA 93.837—Cardiovascular Diseases Research) on September 2, 2025, to develop the first high-speed wearable speckle contrast optical spectroscopy (SCOS) system for cuffless ambulatory blood pressure monitoring. The project addresses a critical clinical need: while traditional periodic cuff-based blood pressure measurements remain the standard of care,...

The University of Rochester has received a $665,724 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2026 through March 31, 2030. This research project investigates the cardioprotective mechanisms of exercise by examining the role of the NRF2 (Nuclear Factor Erythroid-Derived 2) stress-responsive transcription factor and its antioxidant gene program in cardiac fibroblasts. The...

Federal Grant Award Summary The University of Alabama at Birmingham received a $162,703 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with a completion date of July 31, 2030. This project focuses on implementing streamlined, standardized blood pressure (BP) measurement protocols in primary care settings. The award supports research and implementation work to develop and...

ENHANCE-O2 Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant of $1,507,442 under the Cardiovascular Diseases Research program (CFDA 93.837) effective May 1, 2026 through January 31, 2031. The ENHANCE-O2 project investigates pulse oximeter accuracy and clinical outcomes in hospitalized patients with shock and acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The research addresses regulatory gaps...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Northwestern University a Project Grant of $793,184 on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the AUTO2 Trial, a 2×2 factorial, patient-randomized controlled trial examining digitally-enabled home blood pressure monitoring strategies for patients with uncontrolled hypertension. The research will evaluate the comparative effectiveness of automated...

This National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research award (CFDA 93.837) of $1,357,595 funds basic and translational research investigating tissue transglutaminase (TG2) as a therapeutic target for obesity-associated arterial stiffening and hypertension. The University of Missouri System, awarded September 1, 2025, through May 31, 2029, will deliver hypothesis-driven mechanistic research combining genetic manipulation, pharmacological experiments, and animal...